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6.7 + 1.9 vs. 13 + 1.4”). Conclusions: 1. LV exhibits dominant “peristaltic”
segment lengths motion pattern of mechanical heterogeneity: apex-to-base
shortening and base-to-apex lengthening sequence; 2. Increased afterload
changes thia pattern to more homogeneouslengthening.
m99569 MagneticResonanceImagingAseeaamantofRegionalMyocardialFiberandCrosa-fiberStrain
D.C. Bloomgarden, V.A. Ferrari, A.A. Young, D.L. Kraitchman, Z.A. Fayad,
L. Axel. Urriv of PA, Phi/a., PA, USA, Urri~ of Auckland, Auck/and, AfZ,USA
Myocardial fiber orientations areorganized consistency.Noninvasive studies
(assuming homogeneous strain) and invasive canine studies under non-
physiological conditions have demonstrated greater subendocerdial cross-
fiber(XF) shortening than fiber shortening. We reexamined this phenomenon
using high resolution MRtegging and nonhomogeneous analysis under phys-
iological hemodynamic conditions. We imaged four normal dogs using MRI
with tissue tagging in shori and long axis planes. Three-dimensional finite el-
ement modeling was used to reconstruct the nonhomogeneous deformation
field of the entire LV.Strain was extracted from the model and referenced to
the fiber and XF directions, using a quantitative fiber field database, at all tag
intersections (- 1350/dog). Data were divided into 36 regions (3 longitudinal
levels, 4 circumferential sectors, and 3 transmural depths). The table shows
repreaentative average regional shortening straina at the midventricle. Fiber
strain varied by only 6’Yoover all regions, compared to 15% for XF strain. XF
strain was greater in the subendocardiurntha in the subepicardium in all
regions, and XF strain was greater than fiber strain throughout the suben-
docardium. High resolution MR tagging with nonhomogeneous 3D analyais
demonstrates striking differences in fiberafid cross-fiber strains in the normal
LV.
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]996-51 ] EfiedsofAn9iotenain~onveflin9~n~Yme
Inhibitor on NitrateToleranceDuringTranedermal
Applicationof Nitroglycerin
H. Watanabe, M. Kakihana’, S. Ohtsuka, Y. Sugishite. LhWersityof
Tsukuh, Tsukubs,Japan, 1Ibaraki Prefectural Universi~ of’Health
Sciences, Ibsraki, Japan
Continuous application of nitroglycerin (NTG) has been shown to result in the
development of nitrate tolerance. The attenuation of intracellular production
of cGMP has been known aa an important mechanism of nitrate tolerance.
Thia study waa designed to investigate the effects of angiotenain mnverting
enzyme (ACE) inhibitors, captopril with a SH group and enalapril without a
SH group, on nitrate tolerance. in 15 patients with congestive heart failure,
platelet cGMPlevels (pmol/l OgPLT)andforearrmblood flow (FBF,mVmifVIOo
ml arm) by plethysmography were measured before and 5 minutes after
sublingual administration of 0.6 mg NTG at the following four phases: (1)
Control phase, (2) NTG phase (1 week after application of transdermal NTG
tape 10 m@24 hr), (S) CPT phase (1 week after both ceptopril 75 mg/day
and NTG tapa), and (4) ENL phase (1 week after both enalapril 10 m@day
and NTG tape). Before sublingual NTG, platelet cGMP levels (NTG: 0.44 +
0.12, CPT: 0.52+ 0.11, ENL: 0.41 + 0.18, p c 0.05 vs control, ANOVA) and
FBF (NTG: 3.3 + 0.5, CPT: 3.5 A 0.4, ENL: 3.5 + 0.5, p <0.05 va control,
ANOVA) were significantly higher at three phases with NTG tape than the
control phase (cGMP: 0.33 + 0.17, FBF: 2.7 + 0.5). The parentage of the
increase of platelet cGMP (% cGMP) and FBF (% FBF) after sublingual
NTG were significantly Iesa at the NTG phase than the control phase (ok
cGMP: 8 + 2 VS 36 + 5, p < 0.01; 7. FBF: 15 + 4 VS 32 + 8, p <0.01,
control phase va NTG phase). In contract, concomitant application with ACE
inhibitors maintained % cGMP (CPT:37+7, ENL: 30+5) and% FBF (CPT:
30& 8, ENL: 31 +7) campared with the control phase. Conclusions: These
results indicate that concomitant therapy with ACE inhibitore may be helpful
to prevent the attenuation of the production of cGMP and vasodilation during
continuous transdermal application of NTG.
IEEz.1ResponaeofB’ac’Hea~Fai’urepat’ent’toCarvediloi
C,Yancy, M.B. Fowler, W.S. Colucci, E.M. Gilbert, MA. Lukae, S.T.Young,
for the US Carvedilol Heart Failure Study Group. University of Texas
Southwestern, Da//as, TX, USA
To determine whether or not race might beaasociated with an altered efficacy
or safety profile when receiving therapy with p-blockade in heart failure, we
compared outcomea among black patiants randomized (double-blind) to
placebo or cervedilol (CRV), a multiple-action drug with & and a-blockade
and antioxidant properties, in the US Carvedilol Heart Failure Trials Program.
This study of 1,094 NYHA Class II-IV patients (LVEFs 35%), included 217
(20%) blacks (B), and 608 (74%) Caucasians (C). The mean exposure for C
(166 days) and B (167 days) was eimilar, during which existing therapy with
digoxin, diuretics andlor ACE inhibition was maintained.
Resu/ts: (Relative risk; 95% confidence intewals; interaction P value)
Race Mortality CardiovascularHospitali- WorseningHeart Failure
p = 0.s05 zation p = 0.342 Hospitalizationp = 0,714
c 0,34 (0.17, 0.67) 0.65 (0.46, 0.91) 0.52 (0.31, 0.S7)
B 0.53 (0,16, 1.52) 0.61 (0.29, 1,24) 0.47 (0.14, 1.61)
Adverse events associated with &blockade (fatigue [24% C, 18% B],
cardiac failure [16Y0C, 17Y0B] and bradycardia [7% C, 5% B]) were similar
in incidence although vasodilation (dizzineas [26% C, 33% B], hypotension
[9% C, 16% B]) waa less common in C.
Cone/usion:Blackpatients treated with CRV had similar reductions in their
risk of death and hospitalization, and exhibited a high degree of tolerability
of therapy.
1996-53] ShouidLowB100dPree5UreprGciIJdeinitiationOf
BetaBlockerTherapyinCongestiveHeartFailure?
J. Kalman, D.K. Levy, M.M. Mannino, R.S. Freudenberger, C. Buchholz,
O.N. Ocampo, M.L. Kukin. The Cardiovascular /nstitute, Mount Sirrai Scfroo/
of Medicine, New York,NY USA
There ia now accumulating evidence of the benefit of fl-blocker (P-B) therapy
in refracto~ heart failure. However, many physicians are un$feretandably
ralucfant to initiate B-B therapy when the systolic blood pressure (SBP)
is below IWJ mmHg. We compared the safaty and efficacy of metoprolol
according to the initial BP in 57 consecutive pts enrolled in B-B protocols.
All pts were on chronic background therapy (digoxin, diuretics, and ACEI)
with a pulmonary cspilla~ wedge pressure (PCW, mmHg) 214. There were
16 pts with SBP s 100 (Low BP) and 41 with SBP >100. Pts were NYHA
II - IV, with 70Y0 in NYHA Ill. Aside from BP derived variables, baseline
parameters were similar in both groups. Baseline (B) and 3 month (LT)
variables of SBP, heart rate (HR, bpm), PCW, aystemic vascular resistance
(SVR, d-s-c), stroke work index (SWI, gm-rnlm2), and ejection fraction (EF)
are shown. (*p <0.05 vs. B w/in grp, #p <0.05 btw grp B to LT)
SBP HR Pcw SJR Swl EF
Low BP: S 94 S9 26 1211 16.5 In
Low BP: LT 101” 67* 18” 1055 31.5* ‘-14*
BP> 100: B 118 Ss 2s 1330 23.1 13
BP > 100: LT 112*# 71” 21” 996* 32,4* “-18*
Nine pts did not complete the study (5: SBP > 100,4: Low BP; p = NS).
The average $ in NYHAwas 1 class while submaximal and maximal exercise
Tin both grps (btw grps; p = NS).
In summary, both grps improved with O-Btherapy with no btw grp differ-
ence in response other than the surprising T in SBP in the low BP grp. Thus,
asymptomatic hypotension does not preclude initiation or response to P-B
therapy.
-1 Threa-YearFoiiOv+UpOf~h.MetoPrololinDiiated
CardiomyopathyTrial
B. Andereson, F.Waagstain. Div. of Cardiology, Sah/grenska University
Hospital, G6teborg, Sweden
The international multicenter Metoprolol in Dilated Cardiomyopathy (MDC)
trial was the first major placabo-controlled trial using beta-blcckera in con-
gestive hea~ failure. The study recruited 383 patients with idiopathic dilated
cardiomyopathy. During the 18 months of the study there was a 34% re-
duction in the primary endpoint, death or need for haarf transplantation (p=
0.058). The aim of the present investigation was to evaluate long-term follow-
up in patients participating in the MDC-trial. Death or heart transplantation
was considered as endpoint.
JACC Febmary 1997 ABSTRACTS -Posrer 285A
l?esu/ts:All investigators were sent a questionnaire concerning vital status
and heart transplantation for each patient 3 years after inclusion in the MDC
trial. Data regarding survival and heart transplantation were obtained in 318
of 383 patients. During the MDC-trial there were 44 deaths (21 placebo and
23 metoprolol). During the 3-year follow-up there were another 27 endpoints
in the patients originally receiving placebo (15 transplantations, 12 deaths),
and 17endpointa in the patients originally on metoprolol (13 transplantations,
4deaths). Transplantation-frw survival was 108 of 135 in the placebo group,
and 122 of 139 in the metoprolol group.
Corrchrs/on.’Although many patients received open treatment with beta-
blockade after the double blind phase of the study, the original trend toward
improved transplantation-free survival was maintained 3 years,after inclusion
In the study. Thus, beta-blockade treatment may induce beneficial effects on
myocardlal recovety that postpone future deterioration.
u ,at,en,8”996-55 Tolerability of Carvediioi Initiation in Heart Faiiure
M.B. Fowler, W.S. Colucci, M.R. Brlstow, M. Packer, E.M. Gilbert,
J.N. Cohn, B. WU,J.Z. Hu, M.A. Lukes, S. Kubo, R. Hershberger,
S. Gottlieb, 1.Pina, for the US Carvedllol Heart Failure Study Group.
Stanford Univerai~, Palo Alto, CA, USA
Instituting p-blockade in heatt failure patients (pts) can be associated with
worsening clinical status orother signs of intolerance. Carvadilol (C), combin-
ing nonselective p-and m+blockade with antioxidant effects, showed benefi-
cial effects on clinioal status, survival and morbidity in the US Carvedilol Heart
Failure Trials Program (NYHA II-IV pts with EF < 35% receiving digoxin, di-
uretics ancflor ACEI). We examined the study population retrospectively as
to the incidence of tolerating initiation. Open challenge”wlth C (mean 14 + 5
days) was followed by Minded (C or placebo) titration to target doses (TD) of
6.25 to 50 mg tWiGedaily.
Results: Initial C dose was 6.25 mg in 97% of 1197 pts challenged; 3%
began at, and 7% at some point received 3.125 mg bid during initiation.
Challenge withdrawals for safety were 5% (worsening CHF 2%, dizziness
1.1%, bradycardia 0.2Y0, death 0.57., other event 1.2%). During blinded
titration (C, 696: placebc, 398), 7SY. and 81% reached target dose, with
2.4Y0and 1.1% withdrawn for adverse event, respectively.Reducing diuretic
dose occurred in 8% of C pts but only 3% of pts on placebo. The incidence of
increasing diuretic or changing ACE dose, or mean up-titration days (19.3)
did not differ between C and placebo.
Conclusion: Target carvedilol dose can be successfully reached in most
heart failure pts. Adjustment of other medication, especially decreasing di-
uretic, may be needed in some patients.
D99656 Moxonidine improvea Heart Rete Variability inPatienta With Heart Faiiure
S.Juul-M611er,K. Swedbarg, K. Dickstein, J. McNay. Ma/mo University
Hospital, Malmo, Sweden
Reduced heart rate variability (HRV) reflects autonomic abnormalities and
carries a negative prognosis in heart failure (HF). Intervention with digitalis,
ACE inhibitora, beta blw”kera, and exercise training improves morbidity and
HRV in patients with HF. 96 patients with NYHA II-HI HF and EF-less than
40% on standard treatment were randomized to receive placebo (P) or
moxonidine (M) 0.1, 0.2 or 0.3 mg bid for three months in a multicenter,
double-blind study. 24 hour Helter ECGS were recorded at pretreatment
baseline and 11weeks.
Average changes were:
Doea,mgbid P 0.1 0.2 0.3
N* 19 22 28 t9
A 24 hr HR**, bpm 1 –1.6 –2.1 –3.6
A SDR-R***,ms 2, 2 10 tz
A PNE**”*,p~mi 185 -32 –41 –48
*Complaterewith NSRwithoutpacemaker;“*HR= heartrate;***SDR-R=atanrtardrJe-
vlatkmof5 minepochsofR-Rintervals;****pNE= ~lasmanorepinephrine
There were correlations between dosage of M and: decrease in HR (P=
0.0S),increase indaytifne SD R-R (P c 0.04) and decrease in PNE (P < 0.01).
We conclude that the increase in HRV and decrease in HR are consistent
with sympathetic inhibition confirmed by reduction in PNE. Moxonidine has
potential therapeutic value due to improvement in autonomic abnormalities
of HF.
m EfiWtSOfCOmbine& Therap~with*CElnhibition
and Angiotenain-il ATI Receptor Biockade in
Moderate Heart Faiiure
M. Tanimura, S. Shevlyagin, H. Shimoyama, S. Goldstein, H.N. Sabbah.
Henry Ford HeWand Vascu/arhrstitute Detroit, M/, USA
Long-term therapy with the ACE inhibitor enalaprii (ENA) was shown to at-
tenuate the progression of LVdysfunction in dogs with moderate heart failure
(HF). In the present study we determined whether combined therapy with
ENA and MK996, an angiotensin-11ATi receptor blocker, is more effective
in improving LV function and chamber remodeling than ENA alone. Stud-
ies were performed in 20 dogs with moderate HF (LV ejection fraction, EF =
35%-400A)produced by intracoronaty mlcroembcdlzations.Seven dogs were
treated for 3 months with ENA (10 mg Bid), 6 with ENA (10 mg Bid) plus
MK996 (5 mg Bid), and 7 were untreated (CON). In all dogs, mean aonic
pressure (MAP), LV EF,end-diastolic (EDV) and end-systolic (ESV) volumes
were measured before and after 3 months of therapy and the change (A) for
each parameter was calculated.
CON ENA ENA+ MK996
A MAP(mmHg) 14+6 -4 * 7 -24 k 7’
A LVEF(%) –10+ 1 3+3* 1l 1“
A LVEDV(ml) 16+3 4 *2* -1 *I*
A LVESV(ml) 18+3 1 * 3“ –1 l 1“
*P <0.01 VS.CON
Despite a marked reduction in MAP, combined therapy with ENA and
MK996 was similar to ENA alone in its ability to prevent the progressive da-
ciinein EFand the increase in EDV and ESV seen in CON dogs. Cone/us/on:
In dogs with moderate HF,combining ATI receptor blockade therapy to ACE
inhibition does not improve LVfunction and remodeling beyond that accrued
by ACE inhibition alone.
1996-701 Differen.esBeWeenReapOn*e*t~~ei~~iPinein
Heart Faiiure With and Without Coronary Disease:
V-HeFT iii
J.N. Cohn, T. Germanson, S. Ziesche, for the V-HeFT Study Group.
Minneapolis, MN, USA
Recent data have suggested the possibility of a differential therapeutic re-
sponse in heart failure due to corona~ disease (CAD), and non-ischemic
cardiomyopathy (non-CAD). The V-HeFT Ill data base was examined to
compare the response to the calcium antagonist felodipine 5 mg b.i.d. in
these populations.
Baseline observations:
CAD NON-CAD
246 204
lge (years) 64.5 61 .9”
Race (% white) 82 62*
Hypertensionhistoty(“A) 44 59*
Bloodpressure(S/D mmHg) 121i73 123r75
Heart rate (beattimin) 74.0 75.7
LV EjectionFraction(EF) (“A) 28.1 31 .5”
Exerciasduration(rein) 9,4 9.6
Plasma norepinephrine(pgiml) 508 512
Plasme strialpeptide (p@ml) 122 125
Ventriculartachycardia(%) 60 62
EF increased similarly at3months in responseto felodipine in both groups
(CAD, +1.6; non-CAD, +2.7) vs. placebo (CAD, +0.4, non-CAD, -0.6). There
was a trend for a more favorable response to felodipine at 12 months in non-
CAD than in CAD groups in exercise tolerance (+0.6 vs Orein) and plasma
norepinephrine (–10 p@mlvs. +57 p~ml) despite a similar incidence of new
ventricular tachycardia and no difference in the effect of F on mortality.
Therefore, patients with CAD were older and had a lower EF than non-
CAD heart failure patients. Felodipine exerted a somewhat greater effect on
non-motality end-points in the non-CAD group, but the effects on EF and
motiality were similar.
m BenefiCieiHemOdYnami.~~e.tsofA.u~e
inauiin-Like Growth Factor-1in Patients With
Chronic Heart Faiiure
G. Sutsch, M. Donath, X.-W. Yan, H.-P. Brunner, F. Follath, E.R. Froasch,
W. Kiowski. Cardiology and Endocrinolog~ University Hoapital, Ziirich,
Switzerland
Insulin-1ikegrowth factor-1(IGF) enhances myofibrillar development in vitro
